A study has uncovered that iron orchestrates the activation of two damaging cell death pathways—ferroptosis and ...

RHHBY's member company, Genentech, obtains FDA nod for TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.

Researchers at Karolinska Institutet have identified a new mechanism that may improve the treatment of ischemic stroke. The ...

Ischemic stroke continues to rank among the top causes of death and long-term disability globally. While advances in acute treatments like clot retrieval and thrombolysis have improved outcomes, the ...

According to Roche subsidiary Genentech, which announced the label expansion on Monday, TNKase is the first new drug for ...

STROKE REMAINS a significant health concern in the United States. According to the American Heart Association, it is the ...

MANILA, Philippines – The launch of the Pasig Bigyang Buhay Muli Phase 3, originally set Monday, was postponed to a later date due to inclement weather. According to Deputy Social Secretary Dina ...

Italo Linfante I, Clark W, Haussen DC, et al. HEMERA‐1 CarboxyHEMoglobin OxygEn Delivery for Evascularization in Acute Stroke: A Prospective, Randomized Phase ...

"Everyone at this meeting is aware that transatlantic relations, the NATO alliance and our friendship with the United States have entered a new phase. We all see that," Polish Prime Minister ...

Meanwhile, Bristol Myers Squibb’s oral Factor XIa inhibitor milvexian is currently in Phase 3 testing in acute coronary syndrome, atrial fibrillation, and secondary stroke prevention.